Fig. 3From: Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trialPost-COVID neuropsychological symptoms at 12 weeks after initial infection Forest plot in fluvoxamine and placebo groups using odds ratioBack to article page